GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DaVita Inc (NYSE:DVA) » Definitions » EV-to-EBIT

DVA (DaVita) EV-to-EBIT : 12.11 (As of May. 11, 2025)


View and export this data going back to 1995. Start your Free Trial

What is DaVita EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, DaVita's Enterprise Value is $24,231 Mil. DaVita's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $2,001 Mil. Therefore, DaVita's EV-to-EBIT for today is 12.11.

The historical rank and industry rank for DaVita's EV-to-EBIT or its related term are showing as below:

DVA' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.24   Med: 14.38   Max: 21.68
Current: 12.11

During the past 13 years, the highest EV-to-EBIT of DaVita was 21.68. The lowest was 8.24. And the median was 14.38.

DVA's EV-to-EBIT is ranked better than
66.37% of 449 companies
in the Healthcare Providers & Services industry
Industry Median: 16.43 vs DVA: 12.11

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. DaVita's Enterprise Value for the quarter that ended in Dec. 2024 was $25,235 Mil. DaVita's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $2,001 Mil. DaVita's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 7.93%.


DaVita EV-to-EBIT Historical Data

The historical data trend for DaVita's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DaVita EV-to-EBIT Chart

DaVita Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.57 13.40 14.94 13.78 12.61

DaVita Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.78 14.61 13.77 14.44 12.61

Competitive Comparison of DaVita's EV-to-EBIT

For the Medical Care Facilities subindustry, DaVita's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DaVita's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, DaVita's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where DaVita's EV-to-EBIT falls into.


;
;

DaVita EV-to-EBIT Calculation

DaVita's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=24230.948/2000.862
=12.11

DaVita's current Enterprise Value is $24,231 Mil.
DaVita's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,001 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DaVita  (NYSE:DVA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

DaVita's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2024 ) =EBIT / Enterprise Value (Q: Dec. 2024 )
=2000.862/25235.2268
=7.93 %

DaVita's Enterprise Value for the quarter that ended in Dec. 2024 was $25,235 Mil.
DaVita's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,001 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DaVita EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of DaVita's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


DaVita Business Description

Traded in Other Exchanges
Address
2000 16th Street, Denver, CO, USA, 80202
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.
Executives
Berkshire Hathaway Inc 10 percent owner 3555 FARNAM STREET, OMAHA NE 68131
Javier Rodriguez officer: Chief Executive Officer, DKC 601 HAWAII ST., EL SEGUNDO CA 90245
Joel Ackerman officer: Chief Financial Officer COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR SUITE 900, BETHESDA MD 20817
Michael David Staffieri officer: Chief Operating Officer, DKC 2000 16TH STREET, DENVER CO 80202
Kathleen Alyce Waters officer: Chief Legal Officer C/O DAVITA INC., 2000 16TH STREET, DENVER CO 80202
Barbara J Desoer director CITIGROUP INC., 388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10013
James O Hearty officer: Chief Compliance Officer 2000 16TH STREET, DENVER CO 80202
Christopher Michael Berry officer: Chief Accounting Officer C/O SONDER HOLDINGS INC., 101 15TH ST., SAN FRANCISCO CA 94103
Wendy Lee Schoppert director 6105 TRENTON LANE NORTH, MINNEAPOLIS MN 55442
Phyllis R Yale director
Charles Berg director, officer: Executive Chair, DMG 48 MONROE TURNPIKE, TRUMBULL CT 06611
John M Nehra director 1119 ST PAUL ST, BALTIMORE MD 21202
Adam H Schechter director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Jason M. Hollar director 3333 BEVERLY ROAD, HOFFMAN ESTATES IL 60179
Paula A Price director ONE CVS DRIVE, WOONSOCKET RI 02895